164 related articles for article (PubMed ID: 23016917)
1. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.
Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A
Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917
[TBL] [Abstract][Full Text] [Related]
2. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
3. p63 expression in giant cell-containing lesions of bone and soft tissue.
de la Roza G
Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB
Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965
[TBL] [Abstract][Full Text] [Related]
5. Giant cell tumor of bone express p63.
Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA
Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114
[TBL] [Abstract][Full Text] [Related]
6. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience.
Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A
Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519
[TBL] [Abstract][Full Text] [Related]
8. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].
Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C
Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573
[TBL] [Abstract][Full Text] [Related]
9. Increased numbers of P63-positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis.
Zhou Q; Chang H; Zhang H; Han Y; Liu H
Diagn Pathol; 2012 Sep; 7():119. PubMed ID: 22963430
[TBL] [Abstract][Full Text] [Related]
10. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.
Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C
Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342
[TBL] [Abstract][Full Text] [Related]
11. Regulators of skeletal development: a cluster analysis of 206 bone tumors reveals diagnostically useful markers.
Horvai AE; Roy R; Borys D; O'Donnell RJ
Mod Pathol; 2012 Nov; 25(11):1452-61. PubMed ID: 22766796
[TBL] [Abstract][Full Text] [Related]
12. Nuclear p63 expression in osteoblastic tumors.
Kallen ME; Sanders ME; Gonzalez AL; Black JO; Keedy VL; Hande KR; Homlar KC; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Cates JM
Tumour Biol; 2012 Oct; 33(5):1639-44. PubMed ID: 22623071
[TBL] [Abstract][Full Text] [Related]
13. A Comparative Analysis of p63 Expression in Giant Cell Tumour (GCT), Central Giant Cell Granuloma (CGCG) and Peripheral Giant Cell Granuloma (PGCG).
Nagar SR; Bansal S; Jashnani K; Sinha A; Desai RS
Head Neck Pathol; 2020 Sep; 14(3):733-741. PubMed ID: 31873936
[TBL] [Abstract][Full Text] [Related]
14. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions.
Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN
Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.
Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP
Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430
[TBL] [Abstract][Full Text] [Related]
16. The co-expression of cytokeratin and p63 in epithelioid angiosarcoma of the parotid gland: a diagnostic pitfall.
Lin XY; Liu Y; Zhang Y; Yu JH; Wang EH
Diagn Pathol; 2012 Sep; 7():118. PubMed ID: 22943673
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta isoform and receptor expression in giant cell tumor and giant cell lesions of bone.
Franchi A; Benvenuti S; Masi L; Malentacchi C; Arganini L; Brandi ML; Santucci M
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):170-5. PubMed ID: 11396635
[TBL] [Abstract][Full Text] [Related]
18. Occasional staining for p63 in malignant vascular tumors: a potential diagnostic pitfall.
Kallen ME; Nunes Rosado FG; Gonzalez AL; Sanders ME; Cates JM
Pathol Oncol Res; 2012 Jan; 18(1):97-100. PubMed ID: 21667345
[TBL] [Abstract][Full Text] [Related]
19. Is Core Needle Biopsy Reliable in Differentiating Between Aggressive Benign and Malignant Radiolucent Bone Tumors?
Hegde V; Burke ZDC; Park HY; Zoller SD; Johansen D; Kelley BV; Levine B; Motamedi K; Federman NC; Seeger LL; Nelson SD; Bernthal NM
Clin Orthop Relat Res; 2018 Mar; 476(3):568-577. PubMed ID: 29529643
[TBL] [Abstract][Full Text] [Related]
20. p63 as a prognostic marker for giant cell tumor of bone.
Yanagisawa M; Kakizaki H; Okada K; Torigoe T; Kusumi T
Ups J Med Sci; 2013 Mar; 118(1):23-8. PubMed ID: 23033898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
